Collectively, our findings demonstrate the role of AXL in resistance to TKI in CML cells and identify the involvement of PKC and ERK1/2 pathways in AXL accumulation. Here, PRRT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.